HCS 468 Week 5 Operations Decisions and Legal Requirements Example

Twelve Dollars a Specimen: When a Sales Plan Meets the Anti-Kickback Law, the Operations Decision a Laboratory Made and the Corrective Action Plan That Followed

[Student Name]

University of Phoenix

HCS/468: Regulatory and Compliance within the Health Care Industry

Week 5 Assignment

[Instructor Name]

[Date]

The laboratory, its sales plan and the physician practices are composites written for a model paper; legal guidance comes from the sources listed.

In the laboratory's third-quarter planning meeting, the sales director presented a proposal. Twelve large physician practices send a composite independent clinical laboratory about 40% of its specimens. Their medical assistants draw blood, but many specimens arrive unspun, poorly labeled or late for the courier, and competitors are said to pay offices a fee for processing. The director proposed paying each practice $12 for every specimen its staff centrifuge, label and package, estimating that the fee would cut rejected specimens in half and win two practices now using a competitor. This paper analyzes the proposal against federal law, records the decision, describes a problem the review uncovered and presents the corrective action plan that followed.

The Operational Case

The proposal was not frivolous. Rejected specimens mean a second needle stick for the patient, delayed results for the physician and lost revenue for the laboratory. Processing takes real staff time in a busy office. A fee would appear to compensate that work, and the laboratory's rejection rate from these practices, 3.1% compared with 0.9% from its own draw sites, was costing money and goodwill.

The Legal Requirement

Under the federal anti-kickback statute, a person commits a crime by knowingly and willfully offering or paying money, or anything else of value, when one purpose is to win or reward business billed to Medicare, Medicaid or any other federal payer. Because Medicare and Medicaid pay for many of these practices' tests, any payment to the practices that could be seen as rewarding the flow of specimens creates risk. Safe harbors protect certain arrangements, such as personal services contracts with set, fair-market fees that do not vary with the volume or value of referrals. A fee paid for each specimen, by design, varies with volume.

What Federal Guidance Says

Concern about how laboratories court ordering physicians is not new; the industry's first compliance guidance already urged laboratories to watch their marketing and their dealings with physicians closely (Office of Inspector General, 1998). The Office of Inspector General (2014) issued a special fraud alert on laboratory payments to referring physicians, warning that specimen collection, processing and packaging fees paid to physicians who order tests, and payments tied to patient data registries, present substantial risk under the statute, particularly when the physician also bills Medicare for a separate specimen collection fee. The alert noted that payments exceeding fair market value, or tied to the volume of referrals, can be evidence of intent to induce referrals. A laboratory cannot cure a per-specimen fee by calling it compensation for work; the question is whether one purpose of the payment is to keep the specimens coming.

Rights and Responsibilities

Patients have a right to tests ordered for their care, not for a practice's income. Physicians have a responsibility to choose laboratories on quality and service. The laboratory has a responsibility to its employees and owners not to expose them to criminal and civil liability, and the False Claims Act allows claims tainted by a kickback to be treated as false, multiplying the exposure.

The Decision

The compliance committee rejected the fee. It approved three alternatives. First, the laboratory will supply centrifuges on loan with clear labels that they may be used only for its specimens, plus labeling supplies at no charge, since items used solely for the laboratory's own work are treated differently from gifts. Second, it will place its own phlebotomist in the three highest-volume practices, with written rules that the phlebotomist draws and processes only the laboratory's specimens and performs no office tasks. Third, it will train office staff on specimen handling and report each practice's rejection rate monthly.

A Complication

While preparing the decision, the compliance officer audited expense reports from the sales team. Two representatives had already agreed with four practices to pay a monthly "processing allowance" of $300 to $900, recorded as marketing expenses, for 14 months. Payments totaled about $41,000. The practices referred specimens billed to Medicare and Medicaid during the same period.

Corrective and Preventive Action Plan

The Office of Inspector General (2023) asks that a detected problem be looked into quickly, fixed at its source and, where money was paid wrongly, repaid. The laboratory's plan follows those steps.

Who Is Affected

The four practices are not the laboratory's to discipline, but they received payments they may also need to review with their own counsel, and the laboratory's letter ending the arrangement will say so plainly without accusing anyone. Patients whose tests were billed during the period received the tests their physicians ordered; the problem lies in the payments, not in the care. Employees in sales will hear the reasons for the new rules directly from the chief executive rather than through rumor.

Containment

Within two days, the chief financial officer stopped all payments to the four practices, and the representatives were placed on leave pending investigation. The compliance officer preserved emails, contracts and expense records.

Investigation and Root Cause

Outside counsel interviewed the representatives, their manager and the practices' administrators. The root cause analysis found three contributing causes: sales compensation paid entirely on volume growth, no requirement that payments to referral sources be reviewed by compliance and expense categories that allowed payments to physicians to be coded as marketing.

Correction and Repayment

On counsel's advice, the laboratory will evaluate disclosure through the government's self-disclosure process for providers, quantify any overpayment on claims tied to the arrangements and return identified overpayments within the 60 days federal law allows after they are quantified.

Prevention

Every payment to a physician or practice will require a written agreement reviewed by compliance before the first check. Sales compensation will shift to a mix of base salary and bonuses tied to service measures, such as rejection rates and client retention, rather than volume alone. The accounts payable system will block payments coded as marketing to any vendor listed as a referral source. All sales and client services staff will complete training on referral rules, with a signed acknowledgment.

Effectiveness Checks

The compliance officer will audit all payments to referral sources quarterly for two years, check every sales expense report for the next six months and brief the board's audit committee on what those reviews find. The plan will be considered effective when four consecutive quarters show no unreviewed payments.

Conclusion

The sales director was right about the problem and wrong about the fix. Federal law and the government's own guidance made a per-specimen fee too risky, but lawful alternatives addressed the same operational goal. The audit showed that a law is only as strong as the incentives and controls around it, and the corrective action plan changes those, not just the people who broke the rule.

References

Office of Inspector General. (1998). Publication of OIG compliance program guidance for clinical laboratories. Federal Register, 63, 45076-45087. https://www.federalregister.gov/d/98-22559

Office of Inspector General. (2014). Special fraud alert: Laboratory payments to referring physicians. Federal Register, 79, 40115-40118. https://www.federalregister.gov/d/2014-16219

Office of Inspector General. (2023). General compliance program guidance. U.S. Department of Health and Human Services. https://oig.hhs.gov/compliance/general-compliance-program-guidance/